Theriva Biologics to Participate in the A.G.P. Virtual Healthcare Conference
Theriva Biologics to Participate in the A.G.P. Virtual Healthcare Conference
ROCKVILLE, Md., May 14, 2024 (GLOBE NEWSWIRE) -- Theriva Biologics (NYSE American: TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today announced that Company's Management will provide a corporate update and participate in a fireside chat at the A.G.P. 2024 Virtual Healthcare Conference.
馬里蘭州羅克維爾，2024年5月14日（GLOBE NEWSWIRE）——Theriva Biologics（美國紐約證券交易所：TOVX）是一家多元化的臨床階段公司，開發旨在治療高需求領域的癌症和相關疾病的療法。該公司管理層今天宣佈，公司管理層將提供公司最新情況，並參加A.G.P. 2024年虛擬醫療大會的爐邊談話。
A.G.P. 2024 Virtual Healthcare Conference
Format: Fireside Chat
Presentation Date: Tuesday, May 21, 2024
Presentation Time: 7:30 AM ET
Webcast: Click here
A.G.P. 2024 虛擬醫療保健會議
格式：爐邊聊天
演講日期：2024 年 5 月 21 日，星期二
演講時間：美國東部時間上午 7:30
網絡直播：點擊這裏
About Theriva Biologics, Inc.
關於 Theriva Biologics, Inc.
Theriva Biologics (NYSE American: TOVX), is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform designed for intravenous (IV), intravitreal and antitumoral delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient's immune system. The Company's lead candidates are: (1) VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a significant physical and immunosuppressive barrier to cancer treatment; (2) SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci) and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT) recipients; and (3) SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases. For more information, please visit Theriva Biologics' website at .
Theriva Biologics（紐約證券交易所美國股票代碼：TOVX）是一家處於臨床階段的多元化公司，開發的療法旨在治療未得到滿足的高需求領域的癌症和相關疾病。該公司正在推進一種新的溶瘤腺病毒平台，該平台專爲靜脈（IV）、玻璃體內和抗腫瘤輸送而設計，以觸發腫瘤細胞死亡，改善腫瘤共同給藥的癌症療法的可及性，並促進患者免疫系統產生強大而持續的抗腫瘤反應。該公司的主要候選藥物是：（1）VCN-01，一種溶瘤腺病毒，旨在在腫瘤細胞內進行選擇性和攻擊性複製，並降解腫瘤基質屏障，腫瘤基質屏障是癌症治療的重要物理和免疫抑制屏障；（2）SYN-004（ribaxamase），旨在降解胃腸道（GI）內某些常用的靜脈注射β-內酰胺抗生素，以防止微生物組損傷，從而限制VRE（耐萬古黴素腸球菌）等病原生物的過度生長並降低發病率以及異基因造血細胞移植（HCT）接受者的急性移植物抗宿主病（AgvHD）的嚴重程度；以及（3）SYN-020，一種在cGMP條件下產生的腸道鹼性磷酸酶（IAP）酶的重組口服制劑，旨在治療局部胃腸道和全身性疾病。欲了解更多信息，請訪問Theriva Biologics的網站，網址爲。
For further information, please contact:
Investor Relations:
Chris Calabrese
LifeSci Advisors, LLC
ccalabrese@lifesciadvisors.com
917-680-5608
Source: Theriva Biologics, Inc.
欲了解更多信息，請聯繫：
投資者關係：
克里斯·卡拉布雷斯
LifeSci 顧問有限公司
ccalabrese@lifesciadvisors.com
917-680-5608
資料來源：Theriva Biologics, Inc.
譯文內容由第三人軟體翻譯。